Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021
May 04 2021 - 09:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company
dedicated to the development of cellular therapies designed to
reverse disease, today announced its participation in several
industry and investor events:
- BioEquity Europe Digital, May 17-19, 2021
- BioNJ’s 11th Annual BioPartnering Conference, May
18-19, 2021
- Advanced Therapies Congress & Expo (Virtual), May
19-21, 2021
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study in the U.S. for the treatment of
coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12),
recipient of orphan designation for Buerger’s Disease in the
U.S. as well as SAKIGAKE designation and eligible for early
conditional approval in Japan for the treatment of critical limb
ischemia (“CLI”) and Buerger’s Disease based on the results of an
ongoing clinical trial; CLBS201, designed to assess the safety and
efficacy of CD34+ cell therapy as a treatment for diabetic kidney
disease (“DKD”); and OLOGO™ (CLBS14), a Regenerative Medicine
Advanced Therapy (“RMAT”) designated therapy for which the Company
is in discussion with the FDA to finalize a Phase 3 protocol of
reduced size and scope for a confirmatory trial in subjects with
no-option refractory disabling angina (“NORDA”). For more
information on the Company, please
visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John
MendittoVice President, Investor Relations and Corporate
CommunicationsPhone: +1-908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryKelly WakeleePhone:
610.639.2774Email: kwakelee@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2023 to Mar 2024